To Evaluate the Safety, Tolerability and Pharmacokinetics of GST-HG131 Tablets in Single-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Single-dose, Multiple-dose Phase Ia Clinical Trials in Healthy Subjects
Latest Information Update: 07 Jul 2022
At a glance
- Drugs GST-HG131 (Primary)
- Indications Hepatitis B
- Focus First in man; Pharmacokinetics
- Sponsors Fujian Cosunter Pharmaceutical
Most Recent Events
- 11 Apr 2022 Results assessing the safety, tolerability, and pharmacokinetic profile of GST-HG131 in healthy Chinese subjects published in the Antimicrobial Agents and Chemotherapy
- 23 Sep 2020 Status changed from not yet recruiting to recruiting.
- 10 Aug 2020 New trial record